

## Index

### a

acute respiratory distress syndrome  
 (ARDS) 44, 262  
 aluminum gallium nitride high electron  
 mobility transistor (AlGaN/GaN  
 HEMT)-based biosensor 112  
 amperometry 195, 197, 198–199  
 angiotensin-converting enzyme 2 (ACE2)  
 24, 78, 128, 143, 168, 190  
 angiotensin enzyme II (ACE2) 262  
 antibody mimic proteins (AMPs) 115  
 antibody test  
 immunoassays-based detection  
 approach 11–12  
 lateral flow assays 12  
 Vircell and Euroimmun ELISA 11  
 antigenic approach 8–10  
 AP2-associated protein kinase 1  
 SARS-CoV-2 is (AAK1) 263

### b

baricitinib 263  
 biobarriers 90  
 biomarkers 30, 76, 82–84, 92, 109, 110,  
 115, 130, 138, 141, 168, 175, 179,  
 193, 195, 198, 199, 207, 212, 213  
 biosensor 108, 109  
 AlGaN/GaN high electron mobility  
 transistors 130–132  
 applications 95, 109  
 calixarene-functionalized graphene  
 oxide-based sensors 129–130

commercial electrochemical biosensor  
 118  
 for COVID-19 detection 94–95  
 dual-functional plasmonic  
 photothermal sensors 128  
 electrochemical biosensors 109  
 graphene-based field effect transistor  
 (GFET) biosensor 117  
 label-free biosensors 93  
 limitation 95  
 localized surface plasmon coupled  
 fluorescence (LSPCF) fiber-optic  
 biosensor 112  
 market demand 93  
 microcantilever-based biosensor 117  
 molecularly imprinted polymer-based  
 sensors 127  
 nano-based biosensors 93, 95–96  
 nanomaterial-mediated paper-based  
 sensors 126–127  
 optical biosensors 109  
 piezoelectric sensors 109  
 SPR-based biosensor 113  
 zirconium quantum dots 128–129  
 bovine serum albumin (BSA) 115, 148  
 bronchoalveolar lavage (BAL) 27, 166,  
 170, 261

### c

calixarene-functionalized graphene  
 oxide-based sensors 129–130  
 carbon nanomaterials 110

- carbon nanotubes (CNTs) 89–90, 110, 194, 197, 210, 212
- chemical vapor deposition (CVD) 89, 112, 130
- chemiluminescence immunoassay (CLIA) 12, 94, 152
- chemiluminescent immunoassay (CLIA) 191–193
- chlorogenic acid 64, 269
- chloroquine 50, 264, 269
- CO<sub>2</sub> emission
  - data issues and methodology 249–250
  - lower traffic 244
  - residential emissions 248
  - results 251–255
  - sectoral CO<sub>2</sub> emission 245–249
  - sectoral data 244, 245
  - United States 244
  - US IPI and International oil price 247
- colorimetric method 7, 141
- colorimetric paper-based biosensors 112, 126
- complementary DNA (cDNA) receptors 78, 112
- conductometry 195, 197
- conventional enzyme linked immunosorbent assay 113
- coronavirus biosensing, paper-based technology
  - coefficient of variation (CV) values 147
  - colorimetric method 141
  - CRISPR–Cas12-based assay 155
  - fabrication methods 140–141
  - gold nanoparticles (AuNPs) 149
  - lanthanide-doped polystyrene nanoparticles (LNPs) 147
  - lateral flow immunoassay (LFIA) 138
  - nanozyme-based chemiluminescence paper test 152
  - paper-based analytical devices (PADs) 137
  - SARS-CoV-2 spike protein (S-RBD) 154
- coronavirus murine hepatitis virus (MHV) prototype 142
- COVID-19
  - air quality and environmental pollution 228–231
  - antiviral vaccine 222
  - cases and deaths 222, 223
  - clinical expression of 207
  - contact/aerosols/via consumption 222
  - conventional medicines 262–264
  - ecological parameters and soil systems 233
  - environmental management 225–226
  - environmental parameters 224
  - environmental variables 226–228
  - geographical distribution of 51
  - globally 59
  - indirect effects, of environment 235–236
  - infection and control 49–50
  - laboratory diagnosis for
    - antibody test 10
    - antigenic approach 8–10
    - genomic sequencing detection approach 13–14
    - miniaturization detection approach 12–13
    - neutralization detection approaches 13
    - SARS-CoV-2 testing 3–4
  - nanoparticles, detection 265
  - nanopeptide-based vaccines 68
  - nanopore target sequencing (NTS) 268–269
- nanotechnology 60
  - biosensor 63
  - nanopore assisted target sequencing 63–64
  - point-of-care diagnosis 63
  - RT-PCR 62
  - in treatment 269–270
- nanovaccines 60–61
- nano-VLP subunit vaccines 67–68
- noise pollution, increased solid wastes and recycling 234

- nucleoside analog vaccines 65–67
- optical biosensor nanotechnology  
268
- point-of-care assessments 266–268
- RT-LAMP NBS assay 265–266
- SARS and 46
- screening 64–65
- socioeconomic development 225
- socioeconomic environmental impacts  
of 235
- structure of 45
- symptoms and signs 46
- travel restrictions 222
- types of diagnostic test 208
- wastewater quality and sanitary  
systems 234–235
- water resources and aquatic life  
231–233
- COVID-19 diagnostic
- advanced diagnosis technologies 31
  - artificial intelligence and mass  
healthcare 36
  - challenges 30–31
  - emerging diagnostic tests 33
  - FELUDA 34
  - genetic consequences 27–28
  - immunological consequences
    - rapid antibody tests 29
    - rapid antigen testing 29
    - role of 28–29
  - implications of technology 37–38
  - novel technology 34–35
  - point-of-care tests 34
  - protein testing, computed tomography  
29–30
  - reverse transcriptase loop-mediated  
isothermal amplification  
(RT-LAMP) 34
  - sample collection and testing 26–27,  
31
  - SHERLOCK 35
  - SiRNA 33
  - standard healthcare management  
36–37
  - and treatment 47–49
- cycle quantification value 7
- cytokine storm induction 59
- d**
- dipstick assay 126
- disposable carbon electrode (DEP) 110,  
111
- DNA nanoscaffold hybrid chain reaction  
(DNHCR)-based method 81–83
- DNA–RNA hybridization 128
- dual-functional plasmonic photothermal  
sensors 128
- e**
- eCovSens 10, 79–80, 198
- electric arc discharge (EAD) 89
- electrochemical biosensors 109, 207,  
208
- application of 209–210
  - fabrication of 210–211
  - pictorial representation of 211
  - for SARS-CoV-2 detection
    - amperometry 198–199
    - conductometry 197
    - impedimetry 195–196
    - molecular imprinting technology  
194
    - potentiometric measurements  
196–197
    - voltammetry 197–198
- electrochemical impedance spectroscopy  
(EIS) 195
- electrochemical sensors 89, 108, 119,  
132, 208–214
- electron microscopy (EM) 94,  
187–188
- energy information administration (EIA)  
250
- engineered biorecognition element 113
- enzyme-linked immunosorbent assay  
(ELISA) 11, 93, 94, 113, 138,  
190–191
- ePlex® SARS-CoV-2 8, 118
- equity market volatility infectious disease  
tracker (EMV<sub>i</sub>) 246

**f**

- fabrication methods 140–141
- favipiravir 64, 269
- field-effect transistor (FET) 76, 78–79, 95, 96, 115, 117, 130, 177, 198, 199
- fluorine-doped tin oxide electrode modified with gold nanoparticles (FTO/AuNPs) 111

**g**

- genomic sequencing detection approach 13–14
- gold nanoparticles (AgNP) 7, 34, 50, 88–89, 110–112, 124, 125, 149, 198, 212, 213, 268
- graphene-based field effect transistor (GFET) biosensor 117
- graphene-metal nanoparticles composites 110

**h**

- hydroxy-chloroquine azithromycin 264
- Hydroxychloroquine 64, 264, 269
- hypersensitive troponin I 45

**i**

- IgM antibodies 13, 29, 77, 146, 149, 151, 152, 166, 175, 180, 190
- illumina sequencing 265
- immunosensors 110–111, 198, 209, 212–214

**l**

- label-free electrochemical sensors 213
- laser ablation (LA) technique 89
- lateral flow assay (LFA) 12, 47, 63, 80, 126, 138, 152, 153, 200
- lateral flow immunoassay (LFIA) 117, 138, 154, 155, 190, 191
- lateral flow immunochromatographic strip (LFICS) 95, 207
- LFIA running protocol 153
- localized surface plasmon resonance (LSPR) 76–78, 116, 128, 177

- lockdown 98, 200, 227–229, 231, 233–236, 243–246
- loop-mediated isothermal amplification (LAMP) 6, 34, 94, 96, 114, 155, 172, 181, 194, 265–266
- lopinavir 263, 269

**m**

- microarrays 12–13, 92, 94, 118, 189
- microcantilever-based biosensor 117
- microfluidic paper-based analytical device ( $\mu$ PAD) 126, 140
- Middle East respiratory syndrome coronavirus (MERS-CoV) 43, 76, 108, 110, 212
- Middle East respiratory syndrome-related coronavirus (MERS-CoV) 142
- molecular imaging 90–91
- molecularly imprinted polymer (MIP) based sensors 127, 156
- multi-walled carbon nanotube (MWCNT) 89, 212

**n**

- naked-eye colorimetric method 7
- nanobioengineering approach
  - rapid diagnostic tests (RDTs) 166
  - SARS-CoV-2
    - bioengineered surfaces for 177
    - chemiluminescent immunoassay (CLIA) 191–193
    - detection of virus 187–188
    - digital radiographical biosensing platforms 177–179
    - enzyme-linked immunosorbent assay (ELISA) 190–191
    - lateral flow immunoassays (LFIA) 190
    - loop-mediated isothermal amplification (LAMP) 172
    - microarrays 189
    - nanobioengineered prototypes 177
    - post-infection antibodies 189–190
    - protein-based detection 172–175

- reverse transcription-polymerase chain reaction (RT-PCR) 169–171
  - role of 168–169
  - viral DNA/RNA detection 188–189
  - nanomaterial-mediated paper-based sensors 126–127
  - nanomaterials
    - carbon nanotubes 89–90
    - gold nanoparticles 88–89
    - silver nanoparticles 88
  - nanoparticle-based biosensor (NBS) assay 7, 62, 265–266
  - nanopore assisted target sequencing 63–64
  - nanopore target sequencing (NTS) 268–269
  - nanotechnology 269
    - application, in medicine
      - biobarriers 90
      - early detection 91
      - molecular imaging 90–91
      - nanodiagnosics 91–92
    - in Covid-19 contaminated water 97
    - nanomaterials 90
  - nanotoxicity 98
  - nucleoside analogues 262
  - nucleocapsid proteins 115, 148, 150, 153, 154, 175, 188, 190, 197, 212, 267
- O**
- onventional medicines 262–264
  - optical biosensors 84, 95, 109, 110, 193, 194, 200, 209, 268
- P**
- piezoelectric sensors 109
  - plasmonic photothermal (PPT) effect 77, 116, 128, 177
  - point-of-care assessments 266–268
  - polymerase chain reaction (PCR) primer 4–6, 9, 47, 61, 75, 81, 92, 94, 95, 108, 113, 123, 138, 144, 155, 168–171, 187–189, 207, 261, 265, 269
  - potentiometric measurements 196
- 1-pyrenebutyric acid
    - N*-hydroxysuccinimide ester (PBASE) 32, 115,
  - pyrrolidinyI peptide nucleic acid (PNA) 112
- Q**
- quantum dots (QDs) 50, 110, 128–129, 141, 154, 166, 194
- R**
- rapid diagnostic tests (RDTs) 166
  - real time reverse transcriptase polymerase chain reaction (RT-PCR) 4–12, 14, 24, 26–31, 34, 35, 37, 38, 47, 50, 61, 62, 75, 94, 95, 108, 116–118, 123, 124, 128, 132, 144, 145, 147, 150, 169–172, 179, 187–190, 194, 207, 208, 265
  - receptor-binding domain (RBD) 10, 128, 142, 143
  - recombinase polymerase amplification (RPA) techniques 81
  - remdesivir 64, 263, 264, 269
  - reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) 34, 265
  - ritonavir 263
- S**
- SARS CoV-2 detection
    - biomarkers 83–84
    - cell-based potentiometric biosensor 79
    - CRISPR/Cas12 80–81
    - DNA nanoscaffold hybrid chain reaction (DNHCR)-based method 81–83
    - eCovSens 79–80
    - field effect transistor (FET) 78–79
    - localized surface plasmon resonance (LSPR) sensor 77–78
    - structure and genome 76
  - SARS-CoV-2 testing
    - benchtop-sized analyser 7–8

- SARS-CoV-2 testing (*contd.*)
- droplet digital PCR 6
  - loop-mediated isothermal amplification 6–7
  - nanoparticles amplification process 7–8
  - nested RT-PCR 5–6
  - nucleic acid approach 4
  - real-time PCR 4–5
  - screening suitable specimen cultures 3–4
- Severe Acute Respiratory Syndrome
- Covid-2 (SARS-CoV-2) 4, 23, 43, 44, 59, 75, 107, 124, 142, 165, 179, 187, 221, 261, 262
- Shuanghuanglian oral liquid 64, 269
- silver nanoparticles 88, 112
- Simprova system 174
- single-walled carbon nanotubes (SWCNTs) 89, 197
- SirNA 33
- social distancing 207, 222, 225, 243–246
- specific high-sensitivity enzymatic reporter unlocking (SHERLOCK) 35
- stay at home policy 245, 252, 255, 257
- structural vector autoregressive (SVAR) 245, 249
- surface enhanced Raman scattering (SERS) 141, 207
- surface plasmon resonance (SPR) 76, 94, 95, 110, 113–115, 128, 193, 207
- t**
- travel restrictions 222, 246, 270
- v**
- viral culture 188
- volatile organic compounds (VOCs) 89, 124
- w**
- World Health Organization (WHO) 3, 23, 107, 123, 142, 165, 188, 207, 221, 222, 246
- x**
- Xpert Xpress point-of-care assay 8
- Xpert Xpress test 8
- z**
- zirconium quantum dots 128–129













